How to submit an article

Submit your article-1

Note: the articles sent by e-mail will not be accepted.

Our Journal makes a plagiarism checker by a certificate program.

Upload the Copyright Transfer when you submit the article.

 

ISI Journal Citation Reports® Ranking: 2014, Pharmacology & Pharmacy

5-Year Impact Factor 1.551

2014 Impact Factor: 1.575

Instructions for Authors

European Review for Medical and Pharmacological Sciences (Eur Rev Med Pharmacol Sci) publishes Editorials, Reviews, Original Papers, and Scientific Correspondence on subjects regarding Experimental, Laboratory and Clinical Medicine, and Pharmacology. Eur Rev Med Pharmacol Sci is particularly interested in therapies and diagnostics, including all aspects of translation from bench to bedside: identification of novel therapeutic targets, epidemiology, clinical trials, drug safety and meta-analyses. Reviews should include systematic revision of the literature concerning the treated topics and preferably meta-analyses, original illustration and tables. European Review for Medical and Pharmacological Sciences doesn’t accept for the pubblication “data not shown” or “unpublished data”. Letters are restricted to the discussion of papers already published in the journal, with a maximum of 300 words, one table or figure and up to ten references.

Short Reports and Case Reports will be considered for publication only if of particular interest.  The structured abstract must not exceed 200 words.

Please note that the journal employs a plagiarism detection system. By submitting your manuscript to the journal you accept that your manuscript may be screened for plagiarism against previously published work.

Manuscript Submissions

Authors should submit manuscripts including figures to the Eur Rev Med Pharmacol Sci – Please read and apply the loading instructions given at this site, noting that all information entered during the submission process related to the manuscript should also be included, and be identical to the final submitted version of the manuscript – please see full details under “Presentation of Manuscripts”. Papers must be submitted exclusively to the Journal, and are accepted on the understanding that they have not been, and will not be, published elsewhere. The correspondence for each article must be followed only by the corresponding author. The submission process requires a full declaration of personal interests of all Authors, and funding interests; these details should also be included in the text of the manuscript (see below).

Authorship

Authors must fulfil the following criteria:

  • He/she must have made a substantial contribution to research design, or to the acquisition, analysis or interpretation of data;
  • He/she must have drafted the paper or revised it critically;
  • He/she must have given approval of the submitted and final versions.

Copyright Transfer Agreement: All Eur Rev Med Pharmacol Sci Authors will be required to sign a Copyright Transfer Agreement (click to download PDF) for all papers accepted for publication. Signature of the CTA is a condition of publication and papers will not be passed to the publisher for production unless a signed form has been received. After submission, Authors will retain the right to publish their paper in various media/circumstances. To assist Authors, an appropriate CTA form will be supplied by the editorial office. The original completed Copyright Transfer Agreement must be signed by the corresponding Author and sent by e-mail to European Review for Medical and Pharmacological Sciences. If a paper is accepted for publication, and this form has not been received, there will be a delay in the edited paper appearing in the forthcoming section on the Eur Rev Med Pharmacol Sci website. The Editors retain the usual right to modify the style and length of a contribution (major changes being agreed with the corresponding Author) and to decide the time of publication.

Presentation of Manuscripts

A title page must contain the Authors’ names, appointments and place of work at the relevant time, plus the full contact details of the Corresponding Author including their current e-mail address. A full and a short running title should be given, together with a small number of key words (minimum of three words) for indexing purposes.

The text should start with a structured Abstract, not exceeding 270 words, organized into sections using all of the following headings OBJECTIVE, MATERIALS AND METHODS or PATIENTS AND METHODS, RESULTS, CONCLUSIONS. The paper should then proceed conventionally: Introduction, Background, Aim, Materials and Methods, Results, Discussion, and References (list all Authors and put the numbers in sequence on the text). Pages should be numbered consecutively in Arabic numerals, but tables, footnotes, figure legends (including magnifications), acknowledgements and declaration of interests must be submitted on separate sheets. Review Articles and Systematic Reviews also require a structured summary using all of the following headings: OBJECTIVE, MATERIALS AND METHODS or PATIENTS AND METHODS (e.g. search terms used), RESULTS (avoid vague statements e.g. ‘…will be discussed’), CONCLUSIONS (e.g. need for future studies). For reporting Clinical Trials Conducted by Pharmaceutical Companies Please ensure that clinical trials sponsored by pharmaceutical companies follow the guidelines on Good Publication Practice: http://www.gpp-guidelines.org. These guidelines aim to ensure that such trials are published in a responsible and ethical manner. The guidelines cover companies’ responsibility to endeavour to publish results of all studies, companies’ relations with investigators, measures to prevent redundant or premature publication, methods to improve trial identification, and the role of professional medical writers. Moreover, authors are requested to register the clinical trial presented in the manuscript in a public trials registry, and include the trial registration number at the end of the abstract.

References must be numbered in the order in which they are first mentioned in the text, and should be identified in the text, tables and legends by Arabic numbers in superscript. The form of references adopted by the US National Library of Medicine and used in Index Medicus applies (for more details see the section “References”). References must be verified by the Authors against the original documents.

References

Complete all the references as follow: list all the authors, year without month of publication, delete the number of the single issue after the volume’s number, name of the journal: write the international acronyms without any punctuation; you must put a space after semicolon and colon; moreover, initial and final pages must be entirely reported (NOT 2014;2014:907-15, YES 2014; 2014: 907-915). Delete the PMID and DOI number when you have the data aforementioned.

(NO) Example 1: NAINAN OV, XIA G, VAUGHAN G, MARGOLIS HS. Diagnosis of hepatitis A virus infection: A molecular approach. Clinical Microbiology Reviews 2006:19:63-79.

(YES) Example 1: Nainan OV, Xia G, Vaughan G, Margolis HS. Diagnosis of hepatitis A virus infection: a molecular approach. Clin Microbiol Rev 2006; 19: 63-79.

(NO) Example 2: DA. Baidal, C. Ricordi, M. Garcia-Contreras, A. Sonnino, A. Fabbri. Combination high-dose omega-3 fatty acids and high-dose cholecalciferol in new onset type 1 diabetes: A potential role in preservation of beta-cell mass. Eur Rev Med Pharmacol Sci. 2016 Jul;20(15):3313-8.

(YES) Example 2: Baidal DA, Ricordi C, Garcia-Contreras M, Sonnino A, Fabbri A. Combination high-dose omega-3 fatty acids and high-dose cholecalciferol in new onset type 1 diabetes: a potential role in preservation of beta-cell mass. Eur Rev Med Pharmacol Sci 2016; 20: 3313-3318.

Citation of a book: Scuderi N, Toth BA. International Textbook of Aesthetic Surgery. Springer International Publishing, 2016.

Illustrations

Figure legends should be included in the main text of the manuscript and not form part of the figures. For production purposes, it is best if you can supply figures in TIFF format; however, it is also possible to use Illustrator or Photoshop software saved in the ‘.eps’, ‘.tif’ or ‘.jpg’ format. If you are unable to provide these specified formats, please provide the figures in as many different file formats as soon as possible.

The figure resolution/specification for various types of original figures, at their final size, should be as follows: Line art – Minimum 600 dpi, measuring preferably 13 by 18 cm and no more than 20 by 25 cm in size. Halftone (i.e. both B/W and Colour photographs) – Minimum 300 dpi , measuring preferably 13 by 18 cm and no more than 20 by 25 cm in size. Line and tone (line art and halftone combined) – Minimum 600 dpi, measuring preferably 13 by 18 cm and no more than 20 by 25 cm in size.

For line figures, the lines should be solid, the text in a standard font and not blurred, and the overall image should be sharp and clear. Avoid using tints if possible; if they are essential to the understanding of the figure, try to make them coarse. As a guide, if the electronic files are viewed at 400% on the computer screen and they look blurred or pixellated in any way then they will NOT be of sufficient quality for printing.

Figure and table legends must be able to stand alone in the text and thus full descriptive legends for all figures and tables should be supplied.

Units and Abbreviations

All measurements should be in SI units with the exception of haemoglobin (g/dL) and blood pressure (mmHg). Original observations recorded in other units should be stated, together with the appropriate conversion factors. Standard abbreviations, without punctuation, are used. Units, Symbols and Abbreviations (1988) published by the Royal Society of Medicine, and SI: The International System of Units (1982) from HMSO both provide useful guides. Abbreviations, used sparingly, should follow the first full spelling, in parentheses. A list of abbreviations at the beginning of the article is accepted only if they are more than 8.

Statistics

Methods should be referenced. Two-tailed significance tests should be used unless explicitly stated. Controls should be described as completely as experimental subjects. Measures of location should be accompanied by measures of variability (e.g. mean and confidence intervals) as well as conventional probability values. Clinical trial reports should include the power of the study design.

Ethics

An Ethics Committee should have approved human and animal studies but in questionable matters the Editors reserve the right to reject papers.

Clinical Trials

All clinical trials submitted to European Review for Medical and Pharmacological Sciences for consideration of publication must be registered. The International Committee of Medical Journal Editors (ICMJE) defines a clinical trial as “any research project that prospectively assigns human subjects to intervention or comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome. Studies designed for other purposes, such as to study pharmacokinetics or major toxicity (e.g., phase 1 trials), are exempt.”

For definitions and further information, please see the section titled www.icmje.org/publishing_10register.html found in ICMJE’s Uniform Requirements for Manuscripts Submitted to Biomedical Journals. Please note, however, that unlike ICMJE, ADA does not require trials to be registered before enrollment begins, although Diabetes does encourage this practice. When submitting your manuscript, please include the unique trial number and the name of the registry (e.g., ClinicalTrials.gov or ISRCTN) at the end of the abstract and in your cover letter.

Financial Support

Sources of financial support during the last two years must be acknowledged. Please read the following statements, adding those sections which are relevant at the end of your submitted manuscript under a heading ‘Statement of Interests’.

  1. Authors’ declaration of personal interests: (i) [Name of individual] has served as a speaker, a consultant and an advisory board member for [names of organizations], and has received research funding from [names of organization]. (ii) [Name of individual] is an employee of [name of organization]. (iii) [Name of individual] owns stocks and shares in [name of organization]. (iv) [Name of individual] owns patent [patent identification and brief description].
  2. Declaration of funding interests: (i) This study was funded [in part or in full] by [insert name of funding organization], grant number [insert grant or other identification number]. (ii) The [writing or preparation] of this paper was funded in part by [insert name of funding organization]. (iii) Initial data analyses were undertaken by [name of individuals if not listed as Authors] who are employees of [name company] and received funding from [insert name of funding organization]. (iv) Writing support was provided by [insert name of individual(s)] of [name company] and funded by [insert name of funding organization].

Drug Names

Generic names should, in general, be used. If an Author desires, brand names may be inserted in parentheses. Drug names are spelled out according to the European Pharmacopoeia, but the American spelling should be used after the first use of a drug name.

Revised Articles

Revised articles must be submitted again within 2 months, or else will be considered as rejected.

Galley Proofs

The corresponding Author will receive an e-mail with a pdf file of the galley proof. The galley proof can be downloaded as a PDF (portable document format) file. Acrobat Reader will be required in order to read this file. This will enable the file to be opened, read on screen and printed out in order for any corrections to be added. Excessive changes (i.e. over 100 characters) made by the Author to the proofs, excluding typesetting errors, will be charged separately. Changes to figures and tables have an extra cost. Please check carefully the galley proof (especially regarding the name of Authors, affiliations, and corresponding Authors) as after its approval no further change will be possible.

Before the publication, European Review for Medical and Pharmacological Sciences sends the final galley proof in which only missed misstatements in the previous galley proof can be corrected.

Accepted Articles

The accepted articles must be payed before the publication and not over 6 months, otherwise, it will be withdrawn.

Forthcoming Articles

Abstracts of the articles will appear 50-60 days after acceptance in the European Review for Medical and Pharmacological Sciences Forthcoming section. Abstracts of the articles are, therefore, available as soon as they are ready, without having to wait for the next scheduled print issue. The nature of Early View articles means that they do not yet have volume, issue or page numbers, so Early View articles cannot be cited in the traditional way. They are, therefore, given a Digital Identifier Number (Ahead of print ID: ERMPS), which allows the article to be cited and tracked before it is allocated to an issue. Forthcoming article is also a way to know if a paper has been accepted.

Reprints

Paper reprints shall be charged. Electronic offprints are sent to the first Author at his/her first email address on the title page of the paper, on request. For this reason, please ensure that the name, address and email address of the corresponding Author are clearly indicated on the manuscript title page if he/she is not the first Author of the paper.

Supplements

You can contact Gianni Lombardi (g.lombardi@verduci.it). Our team will be able to provide advice and quotations for supplements.

 

Cost of Publication

Open Special Issue “Drug-Induced Hepatotoxicity”

The fee for each accepted manuscript is Euro 700.00 (plus VAT in Italy) for the articles up to 50,000 characters, references, and spaces included, including 4 half-page figures and 4 half-page tables.

The fee for the articles over 50,000 characters in length and 4 half-page figures and 4 half-page tables will be charged as established via previous agreements.

 

Open Special Issue “Update on Inositols”

The fee for each accepted manuscript is Euro 800.00 (plus VAT in Italy) for the articles up to 40,000 characters, references, and spaces included, including 4 half-page figures and 4 half-page tables.

The fee for the articles over 40,000 characters in length and 4 half-page figures and 4 half-page tables will be charged as established via previous agreements.

 

Standard Track

Main stream administrative process. It can require up to 6 weeks to complete the review process of your manuscript.

Articles up to 13,000 characters, references and spaces included, containing 1 figure and 1 half-page table, are published without charge.

Articles up to 27,000 characters, references, and spaces included, containing 2 half-page figures and 2 half-page tables, are published at the regular standard price is Euro 500.00.

Articles up to 50,000 characters, references, and spaces included, containing 4 half-page figures and 4 half-page tables, are published at Euro 800.00.

Articles over sixteen pages in length shall be charged as established via previous agreements.

Each additional table costs Euro 70.00. Each additional figure costs Euro 50.00.

Works made by Researchers from developing countries may be subject to special conditions/benefits.

Note: In Italy, the fee of publication is plus VAT.

These fees will be applied to the papers submitted by September 2016.

 

SuperFast Track

Priority administrative handling within a designated Fast Track path.

We offer a separate fast appraisal and publication service for manuscripts. If you choose this procedure, it guarantees full peer review in a short time, but it does not guarantee acceptance. Once a manuscript is accepted in its final form, it will be published in a full issue of the journal within 40 days; full details below.

The cost is Euro 1400.00* (plus VAT in Italy).

Note: there is an additional fee – Euro 200.00 – for articles (including 4 figures and 4 half page tables) from 30,000 to 45,000 characters spaces included. Articles over 45,000 characters and with more than 4 figures and 4 tables – spaces included – shall be charged as established via previous agreements.

This service will not slow the standard prompt service provided by the journal.

An invoice will be issued by Verduci Editore for the submission fee on receipt of an initial request to use our “Superfast” process – please provide full details to whom this invoice should be sent (including an email address and/or fax number). This procedure will not be active from July 15th to August 31st.

These fees will be applied to the papers submitted by September 2016.

 

Conflicts of Interest (COI)

At the time of submission, European Review for Medical and Pharmacological Sciences policy requires that authors reveal any COI, including financial interests or connections, direct or indirect, or any other situations that could raise questions of bias in either the reported work or the conclusions, implications, or opinions stated. Disclosed potential COIs should include any relevant commercial or other source of funding for either author(s), or the sponsoring institution, the associated department(s) or organization(s). When considering whether you should declare a COI please consider the following question: Is there any arrangement that would embarrass you or any of your co-authors did not declare and that would emerge after publication and you had not declared it?

As an integral part of the online submission process, Corresponding authors are required to confirm whether they or their co-authors have any conflicts of interest to declare, and to provide details of these. If the Corresponding author is unable to confirm this information on behalf of all co-authors, the authors in question will then be required to submit a completed COI form to the Editorial Office. It is the Corresponding author’s responsibility to ensure that all authors adhere to this policy.

If the manuscript is published, COI information will be communicated in a statement within the published work.

COI in Industry Sponsored Research

Authors whose manuscripts are submitted for publication must declare all relevant sources of funding in support of the preparation of a manuscript. European Review for Medical and Pharmacological Sciences requires full disclosure of financial support as to whether it is from the tobacco industry, the pharmaceutical or any other industry, government agencies, or any other source. This information should be included in the Acknowledgements section of the manuscript.
Authors are required to specify sources of funding for the study and to indicate whether or not the text was reviewed by the sponsor prior to submission, i.e., whether the study was written with full investigator access to all relevant data and whether the sponsor exerted editorial influence over the written text. This information should be included in the cover letter. In addition to disclosure of direct financial support to the authors or their laboratory and prior sponsor-review of the paper, submitting authors are asked to disclose all relevant consultancies within the 12 months prior to submission, since the views expressed in the contribution could be influenced by the opinions they have expressed privately as consultants. This information should be included in the Acknowledgments section of the manuscript.

In the event that a previously undisclosed potential competing interest for an author of a published paper comes to the attention of the editors and is subsequently confirmed with the authors, the undeclared interest will be published as an erratum in a future issue.

COI Policy: Reviewers and Editors

Reviewers must disclose to editors any conflicts of interest that could bias their opinions of the manuscript, and they should disqualify themselves from reviewing specific manuscripts if they believe it to be appropriate. As in the case of authors, silence on the part of reviewers concerning potential conflicts may mean either that such conflicts exist that they have failed to disclose, or that conflicts do not exist. Reviewers must therefore also be asked to state explicitly whether conflicts do or do not exist. Reviewers must not use knowledge of the work, before its publication, to further their own interests. COI for a given manuscript exists when a participant in the peer review and publication process – author, reviewer, and editor – has ties to activities that could inappropriately influence his or her judgment, regardless of whether judgment is, in fact, affected. Financial relationships with industry (for example, employment, consultancies, stock ownership, honoraria, expert testimony), either directly or through immediate family, are usually considered the most important conflicts of interest. However, conflicts can occur for other reasons, such as personal relationships, academic competition, and intellectual passion. External peer reviewers should disclose to editors any conflicts of interest that could bias their opinions of the manuscript and they should disqualify themselves from reviewing specific manuscripts if they believe it appropriate. The editors must be made aware of reviewers’ COI to interpret the reviews and judge for themselves whether the reviewer should be disqualified.” (From the International Committee of Medical Journal Editors Annals of Internal Medicine 118, (8) 646-647).
judge for themselves whether the reviewer should be disqualified.” (From the International Committee of Medical Journal Editors Annals of Internal Medicine 118, (8) 646-647).

Specific Policies

Submission by an editor. A paper submitted by an editor will be handled by one of the other editors who does not have a conflict with the review and who is not at the same institution as the submitting editor. The other editor will select referees and make all decisions on the paper.
Submission by author at same institution as one of the editors. A paper submitted by an author for which there is a potential conflict with who is at the same institution as one of the editors will be handled by one of the other editors. The other editor will select referees and make all decisions on the paper. Submission by family member of editor or by author whose relationship with editor might create the perception of bias. A paper submitted by a family member of one of the editors, or by an author whose relationship with one of the editors might create the perception of bias (e.g. in terms of close friendship or conflict/rivalry), will be handled by another editor. The other editor will select referees and make all decisions on the paper. If in doubt, the editors will consult with the Journal editor.

Potential COI for reviewers. The invitation letter to reviewers will include the following paragraph: ‘If you know or think you know the identity of the author, and if you feel there is any potential COI in your refereeing this paper because of your relationship with the author (e.g. in terms of close friendship or conflict/rivalry) or for any other reason, please declare it. By accepting this invitation, it is assumed there is no potential COI. Standard policy will be not to use a referee if a COI has been declared, but the editors may use their discretion after consulting with one another.